1. Home
  2. CWST vs TGTX Comparison

CWST vs TGTX Comparison

Compare CWST & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Casella Waste Systems Inc.

CWST

Casella Waste Systems Inc.

HOLD

Current Price

$94.53

Market Cap

5.8B

Sector

Utilities

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$31.51

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CWST
TGTX
Founded
1975
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.5B
IPO Year
1997
1995

Fundamental Metrics

Financial Performance
Metric
CWST
TGTX
Price
$94.53
$31.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$119.50
$54.75
AVG Volume (30 Days)
542.6K
1.9M
Earning Date
10-30-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
102.54
N/A
EPS
0.24
2.78
Revenue
$1,795,272,000.00
$531,898,000.00
Revenue This Year
$20.34
$82.31
Revenue Next Year
$7.68
$49.05
P/E Ratio
$396.29
$11.35
Revenue Growth
20.54
100.88
52 Week Low
$82.22
$25.28
52 Week High
$121.24
$46.48

Technical Indicators

Market Signals
Indicator
CWST
TGTX
Relative Strength Index (RSI) 58.51 46.02
Support Level $94.75 $30.54
Resistance Level $97.21 $33.79
Average True Range (ATR) 2.34 1.08
MACD 0.31 0.05
Stochastic Oscillator 69.40 37.69

Price Performance

Historical Comparison
CWST
TGTX

About CWST Casella Waste Systems Inc.

Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company's services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: